Kite, Pfizer to Assess Yescarta-Utomilumab Combination in Lymphoma

Kite, a Gilead Company, and Pfizer said today they will assess a combination therapy for refractory large B-cell lymphoma that combines Kite’s approved chimeric antigen receptor T-cell (CAR-T) treatment Yescarta™ (axicabtagene ciloleucel) with Pfizer’s Phase I immunotherapy candidate utomilumab (PF-05082566).The companies said a multi-center Phase I/II study to be sponsored by Kite is expected to launch in 2018. The study’s results will be used to evaluate options for fur